article thumbnail

Industry Groups Provide Feedback on Sen. Warner’s ‘Cybersecurity is Patient Safety’ White Paper

HIPAA Journal

Mark Warner (D-Va) recently published a white paper framing cybersecurity as a patient safety issue. Warner says the white paper is a starting point to open up a discussion about changes that can be implemented to improve cybersecurity in the sector, rather than a blueprint for change.

HIPAA 115
article thumbnail

Cybersecurity is Now a Patient Safety Issue, Suggests Sen. Warner In Congressional Report

HIPAA Journal

The white paper suggests several areas where policies could be changed to improve cybersecurity in the healthcare industry. Cybersecurity can no longer be viewed as a secondary concern; it must become incorporated into every organization’s – from equipment manufacturers to health care providers – core business models.”.

HIPAA 125
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA, MITRE Update Medical Device Cybersecurity Regional Incident Preparedness and Response Playbook

HIPAA Journal

healthcare organizations, the Food and Drug Administration (FDA) asked MITRE to develop a Medical Device Cybersecurity Regional Incident Preparedness and Response Playbook to help hospitals and healthcare delivery organizations (HDOs) develop a cybersecurity preparedness and response framework.

FDA 96
article thumbnail

Clinical Trial Diversity: Pharma Takes Action to Address Disparities

HIT Consultant

” – The paper sheds light on the critical issue of racial and ethnic diversity in clinical trials, exploring current industry initiatives, their effectiveness, and the future landscape shaped by the FDA’s evolving guidance. .

FDA 90
article thumbnail

What If Costco Designed the Prescription Drugs Sales Model?

Health Populi

Its longer more formal name was The Drug Price Competition and Patent Term Restoration Act of 1984, and it created a pathway for generic drug applications to the FDA. the good old days of bipartisan policy making…another topic for another post]. This turbocharged a viable market for generic drugs in the U.S.,

article thumbnail

The Impact of Generative AI in the Life Sciences Industry

Dot Compliance

For instance, a user could query a generative AI model trained on FDA life sciences regulations about AI use in drug development, and the model would provide a summary based on its training data. Choose an eQMS provider with proven life sciences industry expertise and a platform preconfigured to industry standards like FDA, ISO, and GxP.

FDA 52
article thumbnail

What is CAPA in the Pharmaceutical Industry?

Dot Compliance

Regulatory Compliance Adherence to regulatory requirements, such as those outlined by the FDA’s 21 CFR Part 820, is mandatory for pharmaceutical manufacturers. Download our white paper , “A Step-b-Step Guide to Choosing an eQMS,” to learn more about CAPA and other key capabilities you need in your solution.